Brief: Protara Therapeutics Doses First Patient In Advanced-1 Phase 1 Study Of TARA-002 In Non-Muscle Invasive Bladder Cancer
24/03/2022 12:04
March 24 (Reuters) - Protara Therapeutics Inc TARA.O :
* PROTARA THERAPEUTICS DOSES FIRST PATIENT IN ADVANCED-1
PHASE 1
STUDY OF TARA-002 IN NON-MUSCLE INVASIVE BLADDER CANCER
Source text for Eikon: ID:nGNX85DHNT
Further company coverage: TARA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses